Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 10Active not recruiting 2Terminated 1Suspended 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia 1

Interventions

Specimen Handling 28Magnetic Resonance Spectroscopy 19Biopsy 18Cyclophosphamide 7venetoclax 5Vincristine 5Bevacizumab 5Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Etoposide 4Azacitidine 4pembrolizumab 3fludarabine phosphate 3decitabine and cedazuridine drug combination 3X-Rays 3Taxes 3Radiosurgery 3Radiation 3Prednisone 3Injections 3Doxorubicin 3Cetuximab 3zanubrutinib 2trastuzumab deruxtecan 2prednylidene 2olaparib 2iadademstat 2fludarabine 2durvalumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Inotuzumab Ozogamicin × 90 days × Clear all
NCT04747912 2026-03-30

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

University of Chicago

Phase 2 Suspended
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡